MediciNova (NASDAQ:MNOV) is a biopharmaceutical company primarily engaged in the development of novel therapeutic products to address the unmet medical needs in the treatment of diseases with a focus on neurology. Their operations cover a range of activities from drug development to clinical trials, aiming to bring innovative treatments to market. MediciNova's projects include work on therapies for diseases such as multiple sclerosis, chronic obstructive pulmonary disease (COPD), and amyotrophic lateral sclerosis (ALS), among others. The company's objectives revolve around leveraging its proprietary drug discovery platform to accelerate the development of these treatments, improving patient outcomes, and creating shareholder value by advancing its pipeline of potential therapies towards commercialization.